LEFKOFSKY ERIC P sold $828K of TEM (indirect holdings)

LEFKOFSKY ERIC P (CEO and Chairman) sold 11,848 indirectly-held shares of Tempus AI, Inc. (TEM) at an average of $69.87 ($69.83–$70.58, $0.83M total) across 2 trades on 2026-08-25 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · LEFKOFSKY ERIC P
Published Aug 28, 2026, 12:28 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 28, 2026, 12:34 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$TEM
Bearish
medium confidence
Mentioned
$TEM
Relevance
4/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$TEMBearishLow
01

Why it matters

The disclosed sale provides fresh data on insider sentiment, useful for short‑term traders.

02

Market read

Primary insider sale news; modest materiality but relevant for short‑term price action.

03

What to watch

The CEO retains a sizable stake (150,000 shares) and the sale was pre‑planned, which may mitigate concerns.

Relevance 4/10Novelty 6/10Timing: filing disclosed today

Background

Form 4 filings disclose insider transactions; a 10b5-1 plan allows pre‑arranged sales.

Company-level read

Ticker impact

$TEMBearishMedium confidence
Context

CEO Eric Lefkofsky sold 11,848 shares for $828K via a 10b5-1 plan, reducing his stake to 150,000 shares.

Expected impact

Potential modest downside pressure over the next few days.

Evidence & confidence

A $828K sale by the CEO is material for a mid‑cap biotech, but the amount is modest relative to market cap.

Market effects

May raise questions about Tempus AI's near‑term outlook among biotech investors.

Limited to U.S. biotech sector; no broader regional effect.

Minimal global impact beyond the company's share price.

Counterpoint

The sale could be routine under a pre‑arranged plan and not reflect negative sentiment.

Key entities

  • Tempus AI, Inc.

    Biotech firm focused on AI‑driven clinical data platforms.

  • Eric Lefkofsky

    CEO and Chairman of Tempus AI.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

Med

Tempus CEO Eric Lefkofsky: A Blood Draw Can Catch Returning Cancer 6 to 12 Months Before a Scan

Tempus CEO Eric Lefkofsky reported a record quarter with 23% revenue growth, driven by 32% growth in cancer testing and 33% in data & AI applications. The company signed three $100M+ deals, including with Merck and Bristol Myers Squibb. Tempus claims its blood tests can detect cancer recurrence 6-12 months earlier than scans, leveraging its 600-petabyte data trove and 8,000 hospital integrations. The company is acquiring Personalis to expand into recurrence detection.

$TEMMedAI 8/10

BTIG raises Tempus AI stock price target to $100 on data deals

BTIG raised its price target for Tempus AI (NASDAQ:TEM) to $100, citing strong quarterly results, raised guidance, and significant data deals, including a $200M agreement with Bristol Myers Squibb. The company reported 50% revenue growth and positive adjusted EBITDA. Other analysts also raised price targets, noting strong performance in data and diagnostics segments.

$TEMLow

Jefferies upgrades Tempus AI stock rating to hold, raises price target to $70

Jefferies upgraded Tempus AI (TEM) from Underperform to Hold, raising its price target to $70. The stock, currently at $78.48, has gained 43% in six months. The firm cited strong revenue growth, strategic collaborations, and FDA approval plans. Tempus reported Q3 2026 earnings of $0.07 per share, beating estimates, with revenue up 23% to $411.5 million. Needham raised its price target to $89, citing data business growth.

$TEMMed

Tempus AI Inc (TEM) Q3 2026 Earnings Call Highlights: Revenue Jumps 23%

Tempus AI Inc (TEM) reported Q3 2026 revenue of $411M, up 23%. CEO Lefkofsky expects sustainable 25%+ growth, with oncology and data segments driving performance. The company anticipates mid-2027 breakeven for Personalis' MRD test and predicts strong market share in MRD. Tempus also highlighted long-term data business commitments and AI-driven customer stickiness.